Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: back pain

IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis

  |  

In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…

Characterization of Autoreactive B Cells in Patients with SLE & RA

  |  

Antibody-secreting cells are important for the pathophysiology of SLE and RA, but researchers have been unable to determine how these cells are activated. A new technique is able to distinguish between naïve autoreactive B cells and established antibody secreting cells…

Scientists May Be Closer to A Blood Test for Chronic Fatigue Syndrome

Kate Kelland  |  

LONDON (Reuters)—Scientists in the U.S. say they have taken a step toward developing a possible diagnostic test for chronic fatigue syndrome, a condition characterized by exhaustion and other debilitating symptoms. Researchers at Stanford University School of Medicine say a pilot study of 40 people, half of whom were healthy and half of whom had the…

Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World

Megan Brooks  |  

NEW YORK (Reuters Health)—Rates of osteoporotic fracture were similar three years after starting either denosumab or alendronate in a real-world Danish population-based cohort study. “Previous studies have shown that denosumab is more efficacious than alendronate in increasing bone mineral density (BMD), possibly the best proxy outcome for subsequent fracture risk. However, previous studies were underpowered…

IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results

Will Boggs MD  |  

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) can safely switch from infliximab to the biosimilar CT-P13, though they may face a higher risk of clinical relapse, researchers from Spain report. Recent studies have demonstrated the effectiveness and safety of infliximab biosimilars in patients with IBD, but there are limited data about the effectiveness…

Ethics Forum: Patient Safety at Home—What Are Our Legal & Ethical Responsibilities?

Sarah F. Keller, MD, & Marcy B. Bolster, MD  |  

A 60-year-old woman with a six-month history of retroperitoneal fibrosis transfers her care to you. She initially presented with severe bilateral flank pain radiating to the abdomen and chest. A computerized tomography (CT) angiogram of the abdomen demonstrated an infrarenal abdominal aortic aneurysm surrounded by a thick inflammatory rind entangling the left renal vein and…

Valentyn Volkov / shutterstock.com

Did Shiitake Mushrooms Induce Immune-Mediated Necrotizing Myopathy?

Takeshi Yoshida, MD, Hiroaki Chikazawa, MD, Yoshitaka Kumon, MD, PhD, & Ichizo Nishino, MD, PhD  |  

Idiopathic inflammatory myopathies are heterogenous, acquired immune-mediated muscle diseases. Over the past decade, immune-mediated necrotizing myopathy has been recognized as a subcategory of idiopathic inflammatory myopathy characterized by myofiber necrosis in the absence of prominent inflammatory cells.1 Autoantibodies against signal recognition particle (SRP) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) are thought to be associated with the…

At Vasculitis Conference, Patients Share Hope, Humor & Hardships

Bryn Nelson, PhD  |  

SEATTLE—At the first regional vasculitis patient conference ever held in the Pacific Northwest, a panoramic view of Mt. Rainier on a clear January morning set the tone for a day of optimistic talks about recent successes against the various forms of blood vessel inflammation. One attendee at the Jan. 12 conference, sponsored by the Vasculitis…